Key result
Dexmedetomidine use was associated with a significantly lower risk of 28-day mortality (HR 0.58) compared to non-use in ICU patients with sepsis-induced myocardial injury.
Why the study?
Sepsis-induced myocardial injury carries high mortality, and while dexmedetomidine has shown anti-inflammatory and cardioprotective effects, its impact on prognosis in these patients remains unclear.
Does dexmedetomidine reduce 28-day and in-hospital mortality in patients with sepsis-induced myocardial injury?
Cohort (n=3,921)
No
Does dexmedetomidine reduce 28-day and in-hospital mortality in patients with sepsis-induced myocardial injury?
Hazard Ratio: 0.58 (95% CI 0.417–0.798)
Absolute Event Rate: 18.1% vs 28.6%
p-value: p=0.00089
In a retrospective analysis of the MIMIC-IV database, dexmedetomidine use was associated with significantly lower 28-day and in-hospital mortality in patients with sepsis-induced myocardial injury.
No practice change warranted in sepsis-induced myocardial injury; leaves open confirmation in randomized trials.
Background Sepsis-Induced Myocardial Injury (SIMI) is a serious complication with high in-hospital and 28-day mortality. Dexmedetomidine (DEX), a selective α2-adrenergic receptor agonist, has shown anti-inflammatory and cardioprotective effects, but its impact on SIMI prognosis is unclear. Methods This retrospective study used the MIMIC-IV database, including SIMI patients diagnosed per Sepsis-3 criteria. Propensity score matching (PSM) balanced baseline characteristics, and Cox regression analyzed the association between DEX use and mortality outcomes. External validation was performed using the MIMIC-III database. Results Among 3,921 SIMI patients (375 DEX, 3,546 non-DEX), DEX use showed a trend toward lower 28-day mortality (HR 0.49, 95% CI 0.23–1.05, p = 0.068) and in-hospital mortality (HR 0.45, 95% CI 0.20–1.02, p = 0.055). After PSM, mortality remained lower in the DEX group. ICU and hospital stays were longer in the DEX group, but CRRT use showed no significant differences. External validation confirmed these findings. Conclusion DEX use may reduce 28-day and in-hospital mortality in SIMI patients, providing preliminary evidence for its potential benefits. Further large-scale studies are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Xiao-yan et al. (2025) conducted a cohort in Sepsis-Induced Myocardial Injury (SIMI) (n=3,921). Dexmedetomidine vs. Non-use of dexmedetomidine was evaluated on 28-day mortality (HR 0.58, 95% CI 0.417-0.798, p=0.00089). Dexmedetomidine use was associated with a significantly lower risk of 28-day mortality (HR 0.58) compared to non-use in ICU patients with sepsis-induced myocardial injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: